{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:30:56Z","timestamp":1793500256665,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.ijantimicag.2008.06.003","type":"journal-article","created":{"date-parts":[[2008,8,24]],"date-time":"2008-08-24T04:51:40Z","timestamp":1219553500000},"page":"S60-S65","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S1","title":["New antibiotic agents for bloodstream infections"],"prefix":"10.1016","volume":"32","author":[{"given":"Paschalis I.","family":"Vergidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Falagas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2008.06.003_bib1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/dkm137","article-title":"Daptomycin for endocarditis and\/or bacteraemia: a systematic review of the experimental and clinical evidence","volume":"60","author":"Falagas","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jinf.2006.11.007","article-title":"Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients","volume":"54","author":"Poutsiaka","year":"2007","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1592\/phco.26.3.347","article-title":"Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients","volume":"26","author":"Segreti","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","article-title":"Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"8","author":"Falagas","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/jac\/46.5.775","article-title":"Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin\u2013dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group","volume":"46","author":"Drew","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jac\/44.2.251","article-title":"The efficacy and safety of quinupristin\/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group","volume":"44","author":"Moellering","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1086\/427283","article-title":"Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens","volume":"40","author":"Raad","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib11","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1128\/AAC.49.3.884-888.2005","article-title":"Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus","volume":"49","author":"Chambers","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1128\/AAC.48.4.1313-1319.2004","article-title":"Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases","volume":"48","author":"Mushtaq","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1469-0691.2005.01271.x","article-title":"Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)","volume":"11","author":"Fritsche","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib14","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","article-title":"Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study","volume":"36","author":"Chastre","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib15","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.48.8.3136-3140.2004","article-title":"Activities of doripenem (S-4661) against drug-resistant clinical pathogens","volume":"48","author":"Jones","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jac\/dkm310","article-title":"Antimicrobial susceptibility among organisms from the Asia\/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline","volume":"60","author":"Reinert","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dkl441","article-title":"Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report","volume":"59","author":"Peleg","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib18","series-title":"47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Results of Phase 3 study comparing a tigecycline (TGC) regimen with an imipenem\/cilastatin (IMI) regimen in treatment of patients (Pts) with hospital-acquired pneumonia (HAP)","author":"Maroko","year":"2007"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkn165","article-title":"Tigecycline for the treatment for multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence","volume":"62","author":"Karageorgopoulos","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib21","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/cc3995","article-title":"Toxicity of polymyxins: a systematic review of the evidence from old and recent studies","volume":"10","author":"Falagas","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib22","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1128\/AAC.49.8.3136-3146.2005","article-title":"Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis","volume":"49","author":"Kasiakou","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/01.shk.0000246899.73315.cb","article-title":"When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach","volume":"27","author":"Falagas","year":"2007","journal-title":"Shock"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib24","series-title":"17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"Resistance in Pseudomonas aeruginosa and Acinetobacter spp. from blood in the UK and Ireland, 2001\u20132005","author":"Reynolds","year":"2007"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1586\/14787210.5.4.639","article-title":"Antibiotic-lock therapy for long-term catheter-related bacteremia: a review of the current evidence","volume":"5","author":"Korbila","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib26","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2165\/00003495-200565170-00006","article-title":"Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters","volume":"65","author":"Kasiakou","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2008.06.003_bib27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(05)70218-8","article-title":"Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials","volume":"5","author":"Kasiakou","year":"2005","journal-title":"Lancet Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485790800246X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485790800246X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T02:52:14Z","timestamp":1545792734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485790800246X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":27,"alternative-id":["S092485790800246X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.06.003","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}